[
  {
    "brandName": null,
    "clinicalProgramme": {
      "name": "CDISC Development programme",
      "uid": "ClinicalProgramme_000001"
    },
    "description": "Project to be used for test of CDISC implementation, e.g. SDTM, ADAM",
    "name": "CDISC Dev",
    "projectNumber": "CDISC DEV",
    "uid": "Project_000001"
  },
  {
    "brandName": null,
    "clinicalProgramme": {
      "name": "Modern Insulin",
      "uid": "ClinicalProgramme_000002"
    },
    "description": "Project used for devices and other trials in insulin & devices.",
    "name": "INS",
    "projectNumber": "INS",
    "uid": "Project_000002"
  },
  {
    "brandName": "Levemir\u00ae",
    "clinicalProgramme": {
      "name": "Modern Insulin",
      "uid": "ClinicalProgramme_000002"
    },
    "description": "Insulin Detemir Levemir",
    "name": "Insulin Detemir",
    "projectNumber": "NN304",
    "uid": "Project_000003"
  },
  {
    "brandName": null,
    "clinicalProgramme": {
      "name": "Obesity and NADs",
      "uid": "ClinicalProgramme_000003"
    },
    "description": "Cardio vascular outcome trial Semaglutide-Obesity",
    "name": "CVOT Sema-Obesity",
    "projectNumber": "EX9536",
    "uid": "Project_000004"
  },
  {
    "brandName": null,
    "clinicalProgramme": {
      "name": "GLP-1 analogues",
      "uid": "ClinicalProgramme_000004"
    },
    "description": "Semaglutide obesity - To develop semaglutide for the treatment of obesity by finding the semaglutide dose with the optimal benefit-risk and provide access to patients and providers with a convenient easy to use presentation",
    "name": "Semaglutide obesity",
    "projectNumber": "NN9536",
    "uid": "Project_000005"
  }
]